| abstract |
Methods of screening for substances which affect mammalian MAP kinase pathways, both inhibitors and activators, are provided. Substances identified using the methods as having such an effect are candidate pharmaceuticals for use in treatment of cancer, inflammatory disorders, cardio-vascular disorders or neurological disease. Yeasts are provided for use in the methods. In the yeast, deficiencies in yeast MAPKK kinase and MAPK kinase are complemented by mammalian MAPKK kinase and MAPK kinase. Yeast MAPK may also be replaced with a mammalian homologue and mammalian MAPK phosphatases may be introduced. |